- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01700296
COPD, Inflammation and Rehabilitation
Patients with chronic obstructive pulmonary disease, also known as COPD or emphysema, is like any other with a chronic illness not only affected by the physical discomfort the illness gives. For COPD patients that is: accelerated loss of lung function, conditioning and increased mortality: 25% of patients hospitalized with COPD exacerbation die 12 months later.
Patients are also characterized by various psychological factors such as reduced quality of life, depression, etc.
Therefore, everywhere in the country newly diagnosed COPD patients are offered rehabilitation in Region Zealand which consists of 10 weeks of classes 2 hours, 2 times a week with physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education based on the National Health Service and international recommendations.
In the literature, the effect of rehabilitation on quality of life was measured using a questionnaire (St. George Respiratory Questionnaire (SGRQ)), and the increase in function has been measured using a walk test, but there are no studies which look at the effect on inflammation lungs.
It is important for COPD patients is to prevent exacerbations of the disease, which sometimes requires hospitalization and sometimes treated by their own doctor. It has been proven that inflammation in the lungs is associated with disease severity and exacerbation frequency, and therefore we would like to investigate whether both rehabilitation, close monitoring of patients with time in the pulmonary clinic every 3 months, and instruction in self-administration of medication (antibiotics and corticosteroids) have an effect on especially inflammation in the lungs, number of exacerbations, mortality, lung function and walking capacity.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Næstved, Denmark, 4700
- Naestved Sygehus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The study includes consecutive patients over 18 years admitted to the Medical dept, Næstved hospital with AECOPD (2 of 3 symptoms: increased breathlessness, sputum or purulens thereof) on the basis of known COPD (post-bronchodilator FEV1 <80% and FEV1/FVC <70% ; measured in stable phase, ie. earlier than 4 weeks after AECOPD). Patients included during hospitalization for AECOPD
Exclusion Criteria:
- Patients can not participate if they have asthma (post-bronchodilator FEV1 increased by> 15%), are pregnant, nursing, has known serious comorbidities (eg cancer, chronic liver cirrhosis or hepatitis) or cannot give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
NO_INTERVENTION: Standard Care
"Standard Care": finishing treatment for AECOPD in hospital and after hospital discharge to further control by the GP.
In case of severe symptoms and / or airway obstruction (measured by FEV1) refer patients for follow-up in lung clinic.
The subjects are recorded with the same subjective, clinical, paraclinical and invasive parameters as the "Best care" group
|
|
|
EXPERIMENTAL: Best care
"Best Care": subjects are randomly assigned to the "Best care" regardless MRC class and severity of symptoms through:
|
"Best Care": subjects are randomly assigned to the "Best care" regardless MRC class and severity of symptoms through:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
IL-8 in Sputum
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
IL-8 in serum IL-8 in the BAL fluid
Time Frame: 1 year
|
1 year
|
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
walking distance
Time Frame: 1 year
|
1 year
|
|
exacerbation frequency
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 34431
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD
-
University Medical Center GroningenCompleted
-
Ryme Medical, Inc.Not yet recruitingCOPD | Lung Disease, Chronic Obstructive | COPD Patients | COPD Acute Exacerbation | COPD (Chronic Obstructive Pulmonary Disease) | Lung Disease Airways | COPD Exacerbations
-
Insel Gruppe AG, University Hospital BernUniversity Hospital, Geneva; Cantonal Hospital St. Gallen, SwitzerlandNot yet recruiting
-
Istituto Nazionale di Ricovero e Cura per AnzianiRecruiting
-
Bio-Sensing Solutions S.L. (DyCare)Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Centre...Recruiting
-
Sir Run Run Shaw HospitalRecruiting
-
The First Affiliated Hospital of Guangzhou Medical...Recruiting
-
Association des Réseaux BronchioliteLaboratoire Système et Matériaux pour la Mécatronique (SYMME)Recruiting
-
Polytechnic Institute of PortoNippon Gases PortugalRecruiting
-
China-Japan Friendship HospitalNot yet recruiting
Clinical Trials on Best care
-
Istituto Scientifico Romagnolo per lo Studio e...Completed
-
Hofseth Biocare ASAKGK Science Inc.CompletedCovid-19 | COVIDCanada, Brazil, Hungary, Mexico, Serbia
-
Lepu Biopharma Co., Ltd.Not yet recruiting
-
Emory UniversityNational Cancer Institute (NCI); National Center for Complementary and Integrative...Active, not recruitingLymphoma | Multiple MyelomaUnited States
-
AO GENERIUMCompletedCOVID-19 | Coronavirus Disease 2019Russian Federation
-
Baylx Inc.WithdrawnCOVID-19 | Acute Respiratory Distress Syndrome | ARDS
-
Sheba Medical CenterClalit Health ServicesCompletedChronic Obstructive Pulmonary Disease (COPD)Israel
-
Poniard PharmaceuticalsUnknownSmall Cell Lung CancerIndia, Russian Federation, Argentina, Belarus, Bosnia and Herzegovina, Bulgaria, Chile, Croatia, Hungary, Latvia, Montenegro, Poland, Romania, Serbia, Ukraine
-
University of SouthamptonMcTimoney College of ChiropracticTerminated
-
Duke UniversityUniversity of Colorado, Denver; Northwestern University; University of California... and other collaboratorsCompletedFeasibility of Best Supportive Care Delivery